Global Pharmaceutical Drug Delivery Market Size, Share & Trends Analysis Report By Route of Administration, By Application (Respiratory & Other Diseases, Cancer, Diabetes, and Cardiovascular Diseases), By Regional Outlook and Forecast, 2023 - 2030

Global Pharmaceutical Drug Delivery Market Size, Share & Trends Analysis Report By Route of Administration, By Application (Respiratory & Other Diseases, Cancer, Diabetes, and Cardiovascular Diseases), By Regional Outlook and Forecast, 2023 - 2030

The Global Pharmaceutical Drug Delivery Market size is expected to reach $1.9 trillion by 2030, rising at a market growth of 4.1% CAGR during the forecast period.

Topical drug delivery is used in dermatology to treat various skin conditions, including dermatitis, psoriasis, acne, eczema, and fungal infections. Topical formulations such as creams, ointments, and gels are applied directly to the affected skin, delivering medications to the site of action. Consequently, the topical drug delivery segment would generate approximately 15.03% share of the market by 2030. Topical drug delivery is employed in ophthalmic applications to treat eye conditions like glaucoma, conjunctivitis, and dry eye syndrome. Eye drops, ointments, and gels are applied directly to the eyes, allowing for targeted and efficient drug delivery to the ocular tissues.

The major strategies followed by the market participants are Mergers & Acquisition as the key developmental strategy to keep pace with the changing demands of end users. For instance, In October 2023. Amgen, Inc., a pharmaceutical company, has completed the acquisition of Horizon Therapeutics plc, a biopharmaceutical company. Through this acquisition, Horizon will help to further establish Amgen as a leader across a broader range of diseases. Furthermore, the companies will collaborate to serve even more patients worldwide who are suffering from serious illnesses.

KBV Cardinal Matrix - Pharmaceutical Drug Delivery Market Competition Analysis

Based on the Analysis presented in the KBV Cardinal matrix; Pfizer, Inc. is the forerunner in the Market. In October 2022, Pfizer, Inc., a biopharmaceutical company, took over Global Blood Therapeutics, Inc., a biopharmaceutical company. Through this acquisition, Pfizer will incorporate the portfolio of Global Blood Therapeutics, which will accelerate innovation and the timely introduction of multiple potential best-in-class treatments for people living with sickle cell disease. And Companies such as GlaxoSmithKline PLC (GSK), Johnson & Johnson, and Novartis AG are some of the key innovators in Market.

Market Growth Factors

Increased research and development (R&D) investments enable the development of advanced drug formulations. Novel formulations, including liposomes, nanoparticles, and microparticles, enhance drug solubility, bioavailability, and targeted delivery, improving therapeutic efficacy. Biopharmaceuticals and biosimilars represent a growing segment in drug development. Therefore, the market is expanding significantly due to the increasing investments in research and development.

Nasal drug delivery provides a non-invasive and patient-friendly alternative to traditional routes such as injections. The ease of administration enhances patient compliance and comfort, contributing to the growing adoption of nasal drug delivery systems. The nasal route provides direct access to the CNS through the olfactory and trigeminal nerve pathways. Thus, because of the rising adoption of nasal drug delivery, the market is anticipated to increase significantly.

Market Restraining Factors

High development costs may lead pharmaceutical companies to allocate limited resources to research and development. This constraint can impede the exploration of innovative drug delivery technologies, limiting the industry’s ability to develop novel, more effective solutions. High development costs can contribute to elevated drug prices. This reduced accessibility may hinder the emergence of innovative startups and disruptors, limiting fresh perspectives and novel approaches to drug delivery. Thus, high development costs can slow down the growth of the market.

By Route of Administration Analysis

By route of administration, the market is categorized into topical drug delivery, injectable drug delivery, oral drug delivery, nasal drug delivery, and ocular drug delivery. The oral drug delivery segment covered a considerable revenue share in the market in 2022. Oral drug delivery is one of the most convenient methods for patients. It involves swallowing a pill or liquid, making it widely accepted, and enhancing patient compliance with prescribed medications. Advances in formulation technologies, such as bioenhancers and nanoparticulate delivery systems, have improved the oral bioavailability of certain drugs. This optimization contributes to the effectiveness of the medication. Oral drug delivery suits many drug classes, including small molecules, peptides, and biologics. This versatility enables the delivery of diverse therapeutic agents.

By Application Analysis

Based on application, the market is classified into cancer, diabetes, cardiovascular diseases, respiratory diseases, and others. In 2022, the respiratory diseases segment witnessed the largest revenue share in the market. Inhalation is a common and effective route for administering drugs directly to the lungs. Inhalation therapies are widely used for respiratory diseases such as asthma and COPD. The pharmaceutical industry has developed inhalation devices, including metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), to deliver bronchodilators, corticosteroids, and other medications directly to the respiratory system. Rising levels of air pollution globally contribute to the increasing incidence of respiratory diseases. As the global population is exposed to environmental pollutants, the demand for effective pharmaceutical interventions and drug delivery systems for respiratory health continues to grow.

By Regional Analysis

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired a significant revenue share in the market. The Asia-Pacific region has witnessed a proliferation of biologics and biosimilars in development and production. The region is witnessing innovations in drug delivery technologies, particularly emphasizing novel formulations, nanoparticles, liposomal delivery, and other advanced approaches. Telemedicine and digital health solutions are gaining traction in the Asia Pacific region, especially in countries with large and geographically dispersed populations.

Recent Strategies Deployed in the Market

• 2024-Jan: Cipla (EU) Limited, a wholly owned subsidiary of Cipla Limited, has entered into a collaboration agreement with Kemwell Biopharma Private Limited and Manipal Education & Medical Group. Under this collaboration, the companies will collaborate to develop and market new cell therapy products aimed at addressing significant unmet medical needs in the United States, Japan, and EU regions.
• 2024-Jan: Merck & Co., Inc., a multinational pharmaceutical company, has inked an agreement with Harpoon Therapeutics, Inc., a biotechnology company. Under this agreement, a subsidiary of Merck will acquire Harpoon Therapeutics, Inc. Additionally, this agreement underscores the creativity and dedication of the scientists and clinical development teams at Harpoon.
• 2023-Dec: F. Hoffmann-La Roche Ltd., a pharmaceutical company, has inked an agreement with Carmot Therapeutics Inc., a clinical-stage biotechnology company. Under this agreement, F. Hoffmann-La Roche Ltd. will acquire Carmot Therapeutics Inc.
• 2023-Oct: Amgen, Inc., a pharmaceutical company, has completed the acquisition of Horizon Therapeutics plc, a biopharmaceutical company. Through this acquisition, Horizon will help to further establish Amgen as a leader across a broader range of diseases. Furthermore, the companies will collaborate to serve even more patients worldwide who are suffering from serious illnesses.
• 2023-Aug: Novartis AG, a Swiss multinational pharmaceutical corporation, has acquired Chinook Therapeutics, Inc., a biopharmaceutical company. Through this acquisition, Novartis will utilize the combined resources and expertise to further advance the development of these promising treatments for the benefit of patients with rare, severe chronic kidney diseases.

List of Key Companies Profiled

• GlaxoSmithKline PLC (GSK)
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• Pfizer, Inc.
• Johnson & Johnson
• Novartis AG
• Amgen, Inc.
• Sanofi S.A.
• Cipla Limited
• Merck & Co., Inc.

Global Pharmaceutical Drug Delivery Market Report Segmentation

By Route of Administration

• Injectable Drug Delivery
• Oral Drug Delivery
• Topical Drug Delivery
• Nasal Drug Delivery
• Ocular Drug Delivery

By Application

• Respiratory & Other Diseases
• Cancer
• Diabetes
• Cardiovascular Diseases

By Geography

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific
• LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA